Thrombolytic trials in acute cerebral ischaemia suggest that recanalization of cerebral arteries can be achieved within acceptable safety limits by both intra-arterial delivery and systemic administration of fibrinolytic agents. Incidence of symptomatic intracranial haemorrhage does not frequently appear to limit the use of thrombolytic therapy for stroke. In spite of more than 4 decades of experience with heparin in cerebrovascular disease, disagreement and uncertainty about its use continue. A formal overview of the 10 randomised controlled trials of heparin in over 1000 patients with acute ischaemic stroke suggests uncertain effects on mortality and haemorrhagic transformation.
|Translated title of the contribution||Trombolytic and anticoagulant therapy in acute ischaemic stroke|
|Number of pages||8|
|Journal||Giornale di Gerontologia|
|Publication status||Published - 1994|
ASJC Scopus subject areas
- Geriatrics and Gerontology